Viridian Therapeutics Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Public

  • Employees
  • 252

Employees

  • Stock Symbol
  • VRDN

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $31.44
  • (As of Thursday Closing)

Viridian Therapeutics General Information

Description

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Contact Information

Formerly Known As
miRagen Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 221 Crescent Street
  • Suite 103A
  • Waltham, MA 02453
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 221 Crescent Street
  • Suite 103A
  • Waltham, MA 02453
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Viridian Therapeutics Stock Performance

As of 19-Nov-2026, Viridian Therapeutics’s stock price is $31.44. Its current market cap is $3.57B with 114M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$31.44 $30.12 $13.18 - $34.29 $3.57B 114M 2.13M -$3.83

Viridian Therapeutics Financials Summary

As of 30-Sep-2026, Viridian Therapeutics has a trailing 12-month revenue of $26.3M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,692,063 2,689,759 975,265 988,050
Revenue 26,309 70,849 302 314
EBITDA (462,250) (364,592) (298,809) (254,121)
Net Income (453,584) (342,601) (269,949) (237,734)
Total Assets 1,028,670 899,418 742,403 490,424
Total Debt 243,267 50,693 21,095 21,048
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Viridian Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Viridian Therapeutics‘s full profile, request access.

Request a free trial

Viridian Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Viridian Therapeutics‘s full profile, request access.

Request a free trial

Viridian Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product cand
Drug Discovery
Waltham, MA
252 As of 2025

Cambridge, MA
 

Ann Arbor, MI
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Viridian Therapeutics Competitors (14)

One of Viridian Therapeutics’s 14 competitors is Sarepta Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Sling Therapeutics Venture Capital-Backed Ann Arbor, MI
Intellia Therapeutics Formerly VC-backed Cambridge, MA
Harbour BioMed Formerly VC-backed Shanghai, China
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
You’re viewing 5 of 14 competitors. Get the full list »

Viridian Therapeutics Patents

Viridian Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026128897-A1 Methods for treatment of chronic thyroid eye disease Pending 15-Dec-2024
WO-2026128897-A8 Methods for treatment of chronic thyroid eye disease Pending 15-Dec-2024
WO-2026102438-A1 Method for delivering fc fusion molecule Pending 11-Nov-2024
WO-2026055673-A1 Methods for treatment of thyroid eye disease with an anti-igf-1r antibody Pending 09-Sep-2024
WO-2025151492-A1 Compositions and methods for treatment of thyroid eye disease Inactive 09-Jan-2024 C07K16/2863
To view Viridian Therapeutics’s complete patent history, request access »

Viridian Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Viridian Therapeutics Acquisitions (2)

Viridian Therapeutics’s most recent deal was a Merger/Acquisition with Viridian Therapeutics (Biotechnology) for . The deal was made on 27-Oct-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Viridian Therapeutics (Biotechnology) 27-Oct-2020 Merger/Acquisition Other Pharmaceuticals and Biotechnology
Signal Genetics 13-Feb-2017 Merger/Acquisition Biotechnology
To view Viridian Therapeutics’s complete acquisitions history, request access »

Viridian Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.44 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Viridian Therapeutics’s complete esg history, request access »

Viridian Therapeutics FAQs

  • When was Viridian Therapeutics founded?

    Viridian Therapeutics was founded in 2007.

  • Where is Viridian Therapeutics headquartered?

    Viridian Therapeutics is headquartered in Waltham, MA.

  • What is the size of Viridian Therapeutics?

    Viridian Therapeutics has 252 total employees.

  • What industry is Viridian Therapeutics in?

    Viridian Therapeutics’s primary industry is Drug Discovery.

  • Is Viridian Therapeutics a private or public company?

    Viridian Therapeutics is a Public company.

  • What is Viridian Therapeutics’s stock symbol?

    The ticker symbol for Viridian Therapeutics is VRDN.

  • What is the current stock price of Viridian Therapeutics?

    As of 19-Nov-2026 the stock price of Viridian Therapeutics is $31.44.

  • What is the current market cap of Viridian Therapeutics?

    The current market capitalization of Viridian Therapeutics is $3.57B.

  • What is Viridian Therapeutics’s current revenue?

    The trailing twelve month revenue for Viridian Therapeutics is $26.3M.

  • Who are Viridian Therapeutics’s competitors?

    Sarepta Therapeutics, Sling Therapeutics, Intellia Therapeutics, Harbour BioMed, and ONL Therapeutics are some of the 14 competitors of Viridian Therapeutics.

  • What is Viridian Therapeutics’s annual earnings per share (EPS)?

    Viridian Therapeutics’s EPS for 12 months was -$3.83.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process